アブストラクト | There are case reports of mouth ulcers caused by the coronavirus disease 2019 (COVID-19) messenger ribonucleic acid (mRNA) vaccine; however, the actual number and characteristics of cases are unknown. Therefore, we examined this issue using the Japanese Adverse Drug Event Report (JADER), a large Japanese database. We calculated the reported odds ratio (ROR) of drugs that may be specifically associated with mouth ulcers and assumed that a signal was present if the lower limit of the calculated ROR's 95% confidence interval (CI) was > 1. In addition, the time to symptom onset after administration of the COVID-19 mRNA and influenza HA vaccines was investigated. We found that the JADER database contained 4,661 mouth ulcer cases between April 2004 and March 2022. The COVID-19 mRNA vaccine was the eighth most common causative drug for mouth ulcers, with 204 reported cases. The ROR was 1.6 (95% CI, 1.4-1.9) and a signal was detected. There were 172 mouthulcer cases associated with the Pfizer-BioNTech's COVID-19 mRNA vaccine, 76.2% of which were female. The outcome was no unrecovered cases with the influenza HA vaccine, whereas the COVID-19 mRNA vaccine showed unrecovered cases (Pfizer-BioNTech: 12.2%, Moderna: 11.1%). The median time-to-onset of the mouth ulcers was two days for the COVID-19 mRNA vaccine and one day for the influenza HA vaccine, indicating that mouth ulcers caused by the COVID-19 mRNA vaccine were delayed adverse events. In this study, the COVID-19 mRNA vaccine was shown to cause mouth ulcers in a Japanese population. |
ジャーナル名 | Die Pharmazie |
Pubmed追加日 | 2023/5/16 |
投稿者 | Onoda, T; Tanaka, H; Matsuo, H; Takigawa, M; Satoh, M; Ishii, T |
組織名 | Department of Practical Pharmacy, Faculty of Pharmaceutical Sciences, Toho;University, Chiba.;University, Chiba;, Email: hiroyuki.tanaka@phar.toho-u.ac.jp.;University, Chiba; Clinical Development Department, Daiichi Sankyo Co., Ltd.,;Tokyo.;Department of Pharmacy, Tokyo Metropolitan Geriatric Hospital, Tokyo.;Department of Toxicology and Pharmacology, Division of Pharmacy Practice, Meiji;Pharmaceutical University, Tokyo, Japan. |
Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/37189267/ |